ArticleAmerican journal of translational research2024

Dystrobrevin beta is a promising prognostic biomarker and therapeutic target for hepatocellular carcinoma.

Jin Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.